AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
AstraZeneca Sues to Block Medicare Price Negotiations Over ‘Unintended Consequences’ to Orphan Drug Development
Drugmaker AstraZeneca sued the federal government to block Medicare drug price negotiations on Friday, just days before the government announced [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
